Photo by James Heilman, MD via Wikimedia Commons A group of Canadian dermatologists has proposed the first practical “treat-to-target” framework for chronic hand eczema, aiming to bring more structure and predictability to management of a condition that is both common and highly burdensome for patients. The recommendations, published as an open-access brief report in the Journal of the American Academy of Dermatology, come at a time when an expanding range of therapies for ch

The world’s largest genetics study of ‘moliness’ has uncovered hundreds of genes that play a role in the growth of both moles and melanoma, a discovery that could lead to new ways to prevent and treat the deadliest form of skin cancer. These findings, published in Nature Communications, come from research by a team at QIMR Berghofer Medical Research Institute in Herston, Australia. The team found risk genes linked to biological pathways that could lead to the development of a

Trust levels regarding topical therapy were higher among AD patients than PsO patients

Derm.city is pleased to announce the 5th annual short essay competition on the topic of Inclusivity, Diversity and Equity in Dermatology. This essay competition is organized by the Dermatology Industry Taskforce on Inclusion, Diversity and Equity (DiTiDE), an unincorporated, “ad hoc” committee consisting of Canadian life sciences managers and executives, physicians, and allied parties who are committed to improving the patient experience and outcomes of underrepresented skin

Photo by Svdmolen via Wikimedia Commons Working with mouse models, research led by the University of Michigan has revealed previously hidden biology of how touch-sensitive hairs create itching sensations. This fundamental discovery opens new avenues for better understanding and potentially addressing human health conditions characterized by persistent itchiness. The work, supported in part by funding from the National Institutes of Health, was published in the journal Neuron.

A text message intervention system improved cardiovascular risk behaviours and patient confidence managing their health in adult psoriasis patients

All patients self-identified as non-White and nearly 69% of treated subjects had objectively measured Fitzpatrick skin types IV through VI The IL-23 inhibitor guselkumab demonstrated efficacy out to 100 weeks in the treatment of psoriasis across a spectrum of skin types, according to poster research presented at the 2026 annual meeting of the American Academy of Dermatology (AAD) in Denver. A full report will be published in the June 2026 issue of The Chronicle of Skin & Alle

Second-degree burn wound after two days of healing. Phot by Cjr80 via Wikimedia Commons A topical gel formulation of 4-aminopyridine (4-AP) for the treatment of burn wounds has achieved near-complete closure within 21 days in animal models. The findings were published in the journal Biomaterials. Researchers at the Terasaki Institute for Biomedical Innovation and the University of Arizona College of Medicine have developed the new formulation. The medication is best known und